On Eve Of European Launch, Abbott’s Xience V Outperforms Taxus
This article was originally published in The Gray Sheet
Executive Summary
Abbott is trumpeting the latest findings about its Xience V drug-eluting stent in preparation for next month's European launch
You may also be interested in...
No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?
Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C
No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?
Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C
Abbott launches updated stroke device
Firm announces CE mark approval and European launch of its Emboshield PRO embolic protection system on Sept. 13. The next-generation device is more radiopaque than its predecessor, providing better X-ray visibility, Abbott says. Its small size and enhanced profile position the device as a new option for tortuous vessels, according to the firm. Separately, on Sept. 12 the firm reported an expansion of its manufacturing facility in Ireland to ramp up production of the Xience V drug-eluting stent, expected to debut in October (1"The Gray Sheet" Sept. 11, 2006, p. 5)...